The metabolic revolution, decoded

Name: GLP-1 Clinical Reference & Trial Evidence | GLP-1 Atlas
Creator: Dr Kazmi, FRCP
Keywords: GLP-1, GLP-1 receptor agonist, semaglutide, tirzepatide, type 2 diabetes, obesity, clinical reference

A cinematic, source-referenced atlas of GLP‑1 receptor agonists — mechanism to prescription, distilled for the clinic.

Enter the Atlas Start with the science

9: Clinical modules
40+: Trials indexed
8: Molecular agents

An independent GLP-1 clinical reference for healthcare professionals

GLP-1 Atlas summarises the evidence on GLP-1 receptor agonists and related incretin therapies for doctors, nurses, pharmacists and other clinicians, with a UK prescribing focus. Content is written and clinically reviewed by Dr Kazmi, FRCP. The site is not sponsored by any pharmaceutical company. Key regulatory and trial statements link to their primary sources, such as the MHRA, NICE, trial registries and peer-reviewed publications. It is an educational reference, not a substitute for the current SmPC, the BNF, local formularies or specialist advice.

What the atlas covers

Mechanisms of action: incretin physiology, GLP-1 receptor signalling and effects on the pancreas, gut, brain, heart and kidney.

Drug classes and pipeline: semaglutide, liraglutide, dulaglutide, tirzepatide, oral agents and investigational multi-agonists.

Clinical evidence: landmark cardiovascular, renal, obesity and diabetes trials, including SELECT, SOUL, SURMOUNT and TRIUMPH.

Prescribing guidelines: NICE NG28 and technology appraisals, with ADA, EASD and other international frameworks labelled by jurisdiction.

Patient selection: choosing an agent by comorbidity, treatment goal, route preference and contraindications.

Side effects and safety: gastrointestinal tolerability, dose escalation, pancreatitis, gallbladder disease and red flags.

Special scenarios: renal and hepatic impairment, perioperative care, pregnancy planning and older adults.

Regulatory alerts: dated MHRA, EMA, FDA and NICE safety communications and authorisation changes.

Recent source updates

Semaglutide 7.2 mg: MHRA approved a weekly dose of up to 7.2 mg for adults with BMI ≥30 kg/m² on 6 January 2026. Regulatory alerts

Rybelsus formulation change: 1.5, 4 and 9 mg tablets replace 3, 7 and 14 mg one-to-one. Check strength when switching. Regulatory alerts

Orforglipron (Foundayo): UK authorised on 10 August 2026 for weight management and type 2 diabetes. Drug classes

Retatrutide: TRIUMPH-2 phase 3 results are published; the drug remains investigational. TRIUMPH-2 summary

SURMOUNT-5: tirzepatide reduced weight more than semaglutide in adults with obesity without diabetes (−20.2% vs −13.7% at 72 weeks). Clinical evidence

Targeted source update: 20 October 2026. Last full clinician review: 21 May 2026. A source update is not a complete clinical re-review. See the editorial policy and medical disclaimer.